JP2007509141A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509141A5
JP2007509141A5 JP2006536485A JP2006536485A JP2007509141A5 JP 2007509141 A5 JP2007509141 A5 JP 2007509141A5 JP 2006536485 A JP2006536485 A JP 2006536485A JP 2006536485 A JP2006536485 A JP 2006536485A JP 2007509141 A5 JP2007509141 A5 JP 2007509141A5
Authority
JP
Japan
Prior art keywords
diazaspiro
isobutoxybenzyl
undecane
decane
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006536485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509141A (ja
Filing date
Publication date
Priority claimed from SE0302811A external-priority patent/SE0302811D0/xx
Application filed filed Critical
Publication of JP2007509141A publication Critical patent/JP2007509141A/ja
Publication of JP2007509141A5 publication Critical patent/JP2007509141A5/ja
Pending legal-status Critical Current

Links

JP2006536485A 2003-10-23 2004-10-21 新規ジアザスピロアルカンおよびccr8介在疾患処置のためのその使用 Pending JP2007509141A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302811A SE0302811D0 (sv) 2003-10-23 2003-10-23 Novel compounds
PCT/SE2004/001522 WO2005040167A1 (en) 2003-10-23 2004-10-21 Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases

Publications (2)

Publication Number Publication Date
JP2007509141A JP2007509141A (ja) 2007-04-12
JP2007509141A5 true JP2007509141A5 (cg-RX-API-DMAC7.html) 2007-12-06

Family

ID=29546627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536485A Pending JP2007509141A (ja) 2003-10-23 2004-10-21 新規ジアザスピロアルカンおよびccr8介在疾患処置のためのその使用

Country Status (17)

Country Link
US (1) US20070249648A1 (cg-RX-API-DMAC7.html)
EP (1) EP1678178A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509141A (cg-RX-API-DMAC7.html)
KR (1) KR20060088557A (cg-RX-API-DMAC7.html)
CN (1) CN1898239A (cg-RX-API-DMAC7.html)
AR (1) AR046600A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004284028B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415613A (cg-RX-API-DMAC7.html)
CA (1) CA2542226A1 (cg-RX-API-DMAC7.html)
IL (1) IL174698A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004300A (cg-RX-API-DMAC7.html)
NO (1) NO20062335L (cg-RX-API-DMAC7.html)
SE (1) SE0302811D0 (cg-RX-API-DMAC7.html)
TW (1) TW200528451A (cg-RX-API-DMAC7.html)
UY (1) UY28572A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005040167A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200603174B (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
SE0303090D0 (sv) * 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
JP4845873B2 (ja) * 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
WO2006107252A1 (en) * 2005-04-04 2006-10-12 Astrazeneca Ab Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
CN101155812A (zh) * 2005-04-04 2008-04-02 阿斯利康(瑞典)有限公司 新二氮杂螺烷和它们治疗ccr8介导的疾病的用途
EP1869044A1 (en) * 2005-04-04 2007-12-26 AstraZeneca AB Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
GB0514018D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
CA2669736C (en) 2005-11-03 2017-02-21 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
MX2008015696A (es) * 2006-06-09 2009-02-10 Icos Corp Acidos fenil aceticos sustituidos como antagonistas de dp-2.
KR20090030347A (ko) * 2006-07-19 2009-03-24 아스트라제네카 아베 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도
EP2061791A1 (en) 2006-09-15 2009-05-27 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
KR20090071589A (ko) 2006-09-15 2009-07-01 쉐링 코포레이션 통증 및 지질 대사 장애의 치료에 유용한 아제티딘 및 아제티돈 유도체
CN101534822A (zh) * 2006-09-15 2009-09-16 先灵公司 治疗疼痛、糖尿病和脂质代谢紊乱
WO2008099165A1 (en) * 2007-02-15 2008-08-21 Astrazeneca Ab Piperidine derivatives and their use for treatment of ccr8 mediated diseases
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010151815A2 (en) * 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
PL2547679T3 (pl) 2010-03-19 2016-02-29 Pfizer Pochodne 2,3-dihydro-1H-inden-1-ylo-2,7-diazaspiro[3.5]nonanu i ich zastosowanie jako antagonistów lub odwrotnych agonistów receptora greliny
WO2013066718A2 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
GB201122113D0 (en) * 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
AU2013272288B2 (en) * 2012-06-08 2018-01-18 The United States Government As Represented By The Department Of Veterans Affairs FBXO3 inhibitors
EA201492223A1 (ru) * 2012-06-13 2015-03-31 Ф. Хоффманн-Ля Рош Аг Новые диазаспироциклоалканы и азаспироциклоалканы
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9776979B2 (en) * 2013-09-26 2017-10-03 Sanford-Burnham Medical Research Institute EBI2 modulators
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
UA118201C2 (uk) 2013-11-26 2018-12-10 Ф. Хоффманн-Ля Рош Аг НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
US10562869B2 (en) 2014-03-17 2020-02-18 Remynd Nv Oxadiazole compounds
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
SG11201607839UA (en) 2014-03-26 2016-10-28 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX382355B (es) 2015-04-10 2025-03-13 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
JP6832914B2 (ja) 2015-07-31 2021-02-24 ファイザー・インク Magl阻害薬としての1,1,1−トリフルオロ−3−ヒドロキシプロパン−2−イルカルバマート誘導体および1,1,1−トリフルオロ−4−ヒドロキシブタン−2−イルカルバマート誘導体
MX387736B (es) 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
AU2016328436B2 (en) 2015-09-24 2020-05-14 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
MA42919A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
KR20240113606A (ko) 2015-11-16 2024-07-22 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
CA3050625C (en) 2017-01-20 2021-07-20 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
CN110198944A (zh) 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CR20190423A (es) 2017-03-16 2019-11-01 Hoffmann La Roche Nuevos compuestos biciclícos como inhibidores dobles de atx/ca
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
EP3630745A2 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Covalent inhibitors of kras
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体kras、hrasまたはnrasの調節因子としてのキナゾリン誘導体
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
WO2020028706A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
AR116020A1 (es) 2018-09-03 2021-03-25 Bayer Ag COMPUESTOS DE 3,9-DIAZAESPIRO[5.5]UNDECANO COMO INHIBIDORES DE GGTasa I Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS
CN113207291A (zh) * 2018-10-24 2021-08-03 亚瑞克西斯制药公司 2-(2-丙烯酰基-2,6-二氮杂螺[3.4]辛-6-基)-6-(1h-吲唑-4-基)苄腈衍生物及相关化合物作为用于抑制肿瘤转移的g12c突变kras蛋白的抑制剂
WO2022000443A1 (en) * 2020-07-03 2022-01-06 Nanjing Immunophage Biotech Co., Ltd. Methods and compositions for targeting tregs using ccr8 inhibitors
JP2024505261A (ja) 2021-01-29 2024-02-05 セディラ・セラピューティクス・インコーポレイテッド Cdk2阻害剤およびその使用方法
CN117561058A (zh) 2021-06-26 2024-02-13 塞迪拉治疗股份有限公司 Cdk2抑制剂及其使用方法
CA3235270A1 (en) * 2021-10-13 2023-04-20 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
AR131211A1 (es) 2022-11-30 2025-02-26 Idorsia Pharmaceuticals Ltd Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010201A (en) * 1974-04-12 1977-03-01 The Upjohn Company Organic compounds
US4263317A (en) * 1979-09-06 1981-04-21 Hoechst-Roussel Pharmaceuticals, Inc. Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s
BR9908351A (pt) * 1998-02-04 2001-11-20 Banyu Pharma Co Ltd Compostos, processo para a preparação dosmesmos, e, composição farmacêutica
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
US7560546B2 (en) * 2002-08-09 2009-07-14 Merck & Co., Inc. Tyrosine kinase inhibitors
US20070021498A1 (en) * 2004-10-14 2007-01-25 Nafizal Hossain Novel tricyclic spiroderivatives as modulators of chemokine receptor activity

Similar Documents

Publication Publication Date Title
JP2007509141A5 (cg-RX-API-DMAC7.html)
CA2326324C (en) Nitrogen-containing heterocyclic compound
JP6251183B2 (ja) 置換された縮合ピリミジンおよびトリアジン化合物ならびにその使用
DE60221392T2 (de) Neue pyrrolderivate als pharmazeutische mittel
JP2020519589A5 (cg-RX-API-DMAC7.html)
JP5097696B2 (ja) Vr1拮抗剤としての2,3−置換縮合ピリミジン−4(3h)−オン
JP2009528389A (ja) A2aアデノシン受容体拮抗剤
CA2809911A1 (en) Bicyclic aza heterocycles, and use thereof
JP2002539126A (ja) チロシンキナーゼ阻害剤
PL211125B1 (pl) Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
JPWO2005095419A1 (ja) チアゾロピリミジン誘導体
WO2008043745A1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
AU2015320142B2 (en) Novel imidazopyridazine compounds and their use
MX2012005827A (es) Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
JP2013520407A5 (cg-RX-API-DMAC7.html)
JP2006520397A (ja) 新規融合トリアゾロン類及びその使用
JP5487100B2 (ja) アデノシンa3受容体リガンドとしてのトリアゾロ[1,5−a]キノリン
JP2011042653A (ja) アデノシン受容体リガンドとして有用なトリアゾロ−キノリン誘導体
US8022085B2 (en) Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
ES2406737T3 (es) Derivados de pirazol con actividad de tirosina quinasa
EP2813509A1 (en) 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives
JP6339564B2 (ja) 抗マラリア剤としてのピリミジノン誘導体
JP4409935B2 (ja) アミノキノリンおよびアミノピリジン誘導体およびそのアデノシンa3リガンドとしての使用
JP2007509866A (ja) チエノピリミジン
ES2263039T3 (es) Derivados de imidazoquinolina como ligandos del receptor a3 de adenosina.